📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK

Published 03/30/2023, 02:54 PM
Updated 03/30/2023, 04:11 PM
© Reuters. U.S. President Joe Biden meets with Argentina's President Alberto Fernandez  (not pictured)  in the Oval Office at the White House in Washington, U.S. March 29, 2023. REUTERS/Jonathan Ernst

By Blake Brittain

(Reuters) - The Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a patent appeal over drug labels involving Teva Pharmaceuticals USA Inc and GlaxoSmithKline (NYSE:GSK) LLC that could have significant ramifications for the generic-drug industry.

The U.S. Solicitor General said Teva's generic version of GSK's heart drug Coreg could not have violated GSK's patent rights because Teva omitted the infringing use of the drug from its labeling.

Such "skinny labels" typically allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents.

A Teva spokesperson said Thursday that the company was pleased with the Solicitor General's recommendation on an "important issue impacting both the pharmaceutical industry and U.S. patent law."

GSK declined to comment on the brief. The Solicitor General's office did not immediately respond to a request for comment Thursday.

GSK sued Teva for patent infringement in Delaware federal court in 2014 over its generic version of Coreg. Teva argued that it followed U.S. Food and Drug Administration instructions to "carve out" a patented method for using the drug to treat heart failure from its label.

A jury sided with GSK and awarded it $235 million in 2017.

The U.S. Court of Appeals for the Federal Circuit affirmed in 2021 that Teva's label, combined with its marketing materials, encouraged doctors to prescribe the generic in an infringing way.

In its petition to the Supreme Court last year, Teva said the ruling would cause "havoc" for skinny labels, which it said are "extraordinarily common" and "save patients and the federal government billions." GSK countered that the case does not threaten generic drugmakers that "operate properly under the law."

© Reuters. U.S. President Joe Biden meets with Argentina's President Alberto Fernandez  (not pictured)  in the Oval Office at the White House in Washington, U.S. March 29, 2023. REUTERS/Jonathan Ernst

The Biden Administration backed Teva on Wednesday, arguing generic drugmakers should be entitled to rely on the FDA's carve-out instructions, which are based on brand-name drugmakers' own statements to the agency.

"The decision below subverts the balance struck by Congress, creates significant uncertainty for FDA and generic manufacturers, and invites gamesmanship by brand-name manufacturers," the government's brief said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.